JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Search

Twist Bioscience Corp

Chiusa

SettoreSettore sanitario

47.79 3.94

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

45.02

Massimo

48.58

Metriche Chiave

By Trading Economics

Entrata

-48M

-27M

Vendite

3M

99M

Margine di Profitto

-27.41

Dipendenti

979

EBITDA

3.2M

-21M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+11.09% upside

Dividendi

By Dow Jones

Utili prossimi

4 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

733M

2.6B

Apertura precedente

43.85

Chiusura precedente

47.79

Notizie sul Sentiment di mercato

By Acuity

50%

50%

152 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Twist Bioscience Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 feb 2026, 23:11 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3 feb 2026, 23:50 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

3 feb 2026, 23:50 UTC

Discorsi di Mercato

Nikkei May Decline After Hitting All-Time High -- Market Talk

3 feb 2026, 23:42 UTC

Discorsi di Mercato

Gold Edges Lower on Possible Technical Correction -- Market Talk

3 feb 2026, 23:41 UTC

Acquisizioni, Fusioni, Takeovers

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3 feb 2026, 23:38 UTC

Utili

AMD Sales Climb on Help From Data-Center Business -- Update

3 feb 2026, 23:29 UTC

Acquisizioni, Fusioni, Takeovers

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3 feb 2026, 23:27 UTC

Acquisizioni, Fusioni, Takeovers

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3 feb 2026, 23:25 UTC

Acquisizioni, Fusioni, Takeovers

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3 feb 2026, 23:23 UTC

Acquisizioni, Fusioni, Takeovers

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3 feb 2026, 23:22 UTC

Acquisizioni, Fusioni, Takeovers

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3 feb 2026, 23:19 UTC

Discorsi di Mercato

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3 feb 2026, 23:19 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

3 feb 2026, 22:56 UTC

I principali Market Mover
Acquisizioni, Fusioni, Takeovers

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3 feb 2026, 22:40 UTC

Utili

Amdocs Extends Collaboration With T-Mobile

3 feb 2026, 22:39 UTC

Utili

Amdocs 1Q Adj EPS $1.81

3 feb 2026, 22:39 UTC

Utili

Amdocs 1Q Rev $1.16B

3 feb 2026, 22:39 UTC

Utili

Amdocs 1Q EPS $1.45 >

3 feb 2026, 22:38 UTC

Utili

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3 feb 2026, 22:30 UTC

Acquisizioni, Fusioni, Takeovers

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3 feb 2026, 22:22 UTC

Acquisizioni, Fusioni, Takeovers

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3 feb 2026, 22:14 UTC

Utili

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3 feb 2026, 22:13 UTC

Utili

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3 feb 2026, 22:12 UTC

Utili

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3 feb 2026, 22:10 UTC

Utili

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3 feb 2026, 22:10 UTC

Utili

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3 feb 2026, 22:10 UTC

Discorsi di Mercato

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3 feb 2026, 22:10 UTC

Utili

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3 feb 2026, 22:09 UTC

Utili

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3 feb 2026, 22:09 UTC

Utili

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Confronto tra pari

Modifica del prezzo

Twist Bioscience Corp Previsione

Obiettivo di Prezzo

By TipRanks

11.09% in crescita

Previsioni per 12 mesi

Media 52 USD  11.09%

Alto 58 USD

Basso 50 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Twist Bioscience Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

6 ratings

6

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

31.56 / 38.6884Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

152 / 352 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat